New drug combo for cervical cancer shows early promise, but trial halted

NCT ID NCT04651127

Terminated Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested a combination of two drugs—toripalimab (an immunotherapy) and chidamide (a targeted therapy)—in women with advanced cervical cancer that had spread or returned. Only 5 participants were enrolled before the study was terminated. The goal was to see if the combination was safe and could shrink tumors, but results are too limited to draw firm conclusions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: toripalimab (an immunotherapy drug) and chidamide (a targeted drug)
What this could lead to: If it works, this combination could offer a new treatment option for advanced cervical cancer that has not responded to standard therapies.
What could go wrong: This was a very early, small trial (only 5 participants) that was terminated, so results are limited. The combination may cause significant side effects and may not prove effective in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical cancer cervical carcinoma Uterine Cervical Neoplasms uterine cervix neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CERVICAL CANCER CERVIX CANCER CERVIX NEOPLASM

Contacts and locations

Locations

Sun Yat-sen University Cancer Centre

Guangzhou, Guangdong, 510060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.